Han Siean Lee
University of Queensland
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Han Siean Lee.
Angewandte Chemie | 2016
Bodil B. Carstens; Géza Berecki; James T. Daniel; Han Siean Lee; Kathryn A. V. Jackson; Han‐Shen Tae; Mahsa Sadeghi; Joel Castro; Tracy O'Donnell; Annemie Deiteren; Stuart M. Brierley; David J. Craik; David J. Adams; Richard J. Clark
α-Conotoxins are disulfide-rich peptides that target nicotinic acetylcholine receptors. Recently we identified several α-conotoxins that also modulate voltage-gated calcium channels by acting as G protein-coupled GABA(B) receptor (GABA(B)R) agonists. These α-conotoxins are promising drug leads for the treatment of chronic pain. To elucidate the diversity of α-conotoxins that act through this mechanism, we synthesized and characterized a set of peptides with homology to α-conotoxins known to inhibit high voltage-activated calcium channels via GABA(B)R activation. Remarkably, all disulfide isomers of the active α-conotoxins Pu1.2 and Pn1.2, and the previously studied Vc1.1 showed similar levels of biological activity. Structure determination by NMR spectroscopy helped us identify a simplified biologically active eight residue peptide motif containing a single disulfide bond that is an excellent lead molecule for developing a new generation of analgesic peptide drugs.
Biochemistry | 2015
Kohei Himeno; Tomoko Inoue; Rodney Honrada Perez; Michelle L. Colgrave; Han Siean Lee; Lai Yue Chan; Sónia Troeira Henriques; Koji Fujita; Naoki Ishibashi; Takeshi Zendo; Pongtep Wilaipun; Jiro Nakayama; Vichien Leelawatcharamas; Hiroyuki Jikuya; David J. Craik; Kenji Sonomoto
Enterocin NKR-5-3B, one of the multiple bacteriocins produced by Enterococcus faecium NKR-5-3, is a 64-amino acid novel circular bacteriocin that displays broad-spectrum antimicrobial activity. Here we report the identification, characterization, and three-dimensional nuclear magnetic resonance solution structure determination of enterocin NKR-5-3B. Enterocin NKR-5-3B is characterized by four helical segments that enclose a compact hydrophobic core, which together with its circular backbone impart high stability and structural integrity. We also report the corresponding structural gene, enkB, that encodes an 87-amino acid precursor peptide that undergoes a yet to be described enzymatic processing that involves adjacent cleavage and ligation of Leu(24) and Trp(87) to yield the mature (circular) enterocin NKR-5-3B.
Journal of Clinical Investigation | 2018
John J. Miles; Mai Ping Tan; Garry Dolton; Sarah A.E. Galloway; Bruno Laugel; Mathew Clement; Julia Makinde; Kristin Ladell; Katherine K. Matthews; Thomas S. Watkins; Katie Tungatt; Yide Wong; Han Siean Lee; Richard J. Clark; Johanne M. Pentier; Meriem Attaf; Anya Lissina; Ann Ager; Awen Myfanwy Gallimore; Pierre J. Rizkallah; Stephanie Gras; Jamie Rossjohn; Scott R. Burrows; David K. Cole; David A. Price; Andrew K. Sewell
Polypeptide vaccines effectively activate human T cells but suffer from poor biological stability, which confines both transport logistics and in vivo therapeutic activity. Synthetic biology has the potential to address these limitations through the generation of highly stable antigenic “mimics” using subunits that do not exist in the natural world. We developed a platform based on D–amino acid combinatorial chemistry and used this platform to reverse engineer a fully artificial CD8+ T cell agonist that mirrored the immunogenicity profile of a native epitope blueprint from influenza virus. This nonnatural peptide was highly stable in human serum and gastric acid, reflecting an intrinsic resistance to physical and enzymatic degradation. In vitro, the synthetic agonist stimulated and expanded an archetypal repertoire of polyfunctional human influenza virus–specific CD8+ T cells. In vivo, specific responses were elicited in naive humanized mice by subcutaneous vaccination, conferring protection from subsequent lethal influenza challenge. Moreover, the synthetic agonist was immunogenic after oral administration. This proof-of-concept study highlights the power of synthetic biology to expand the horizons of vaccine design and therapeutic delivery.
elly Tie Knit Dress Ribbed dee Strap 75d7q & trexyourex.com | 2018
John J. Miles; Mai Ping Tan; Garry Dolton; Sarah A.E. Galloway; Bruno Laugel; Mathew Clement; Julia Makinde; Kristin Ladell; Katherine K. Matthews; Thomas S. Watkins; Katie Tungatt; Yide Wong; Han Siean Lee; Richard J. Clark; Johanne M. Pentier; Meriem Attaf; Anya Lissina; Ann Ager; Awen Gallimore; Pierre J. Rizkallah; Stephanie Gras; Jamie Rossjohn; Scott R. Burrows; David K. Cole; David A. Price; Andrew K. Sewell
Polypeptide vaccines effectively activate human T cells but suffer from poor biological stability, which confines both transport logistics and in vivo therapeutic activity. Synthetic biology has the potential to address these limitations through the generation of highly stable antigenic “mimics” using subunits that do not exist in the natural world. We developed a platform based on D–amino acid combinatorial chemistry and used this platform to reverse engineer a fully artificial CD8+ T cell agonist that mirrored the immunogenicity profile of a native epitope blueprint from influenza virus. This nonnatural peptide was highly stable in human serum and gastric acid, reflecting an intrinsic resistance to physical and enzymatic degradation. In vitro, the synthetic agonist stimulated and expanded an archetypal repertoire of polyfunctional human influenza virus–specific CD8+ T cells. In vivo, specific responses were elicited in naive humanized mice by subcutaneous vaccination, conferring protection from subsequent lethal influenza challenge. Moreover, the synthetic agonist was immunogenic after oral administration. This proof-of-concept study highlights the power of synthetic biology to expand the horizons of vaccine design and therapeutic delivery.
amp; Alexis Gray Flare Fit Dress Alton Z4AwqHZ & trexyourex.com | 2018
John J. Miles; Mai Ping Tan; Garry Dolton; Sarah A.E. Galloway; Bruno Laugel; Mathew Clement; Julia Makinde; Kristin Ladell; Katherine K. Matthews; Thomas S. Watkins; Katie Tungatt; Yide Wong; Han Siean Lee; Richard J. Clark; Johanne M. Pentier; Meriem Attaf; Anya Lissina; Ann Ager; Awen Gallimore; Pierre J. Rizkallah; Stephanie Gras; Jamie Rossjohn; Scott R. Burrows; David K. Cole; David A. Price; Andrew K. Sewell
Polypeptide vaccines effectively activate human T cells but suffer from poor biological stability, which confines both transport logistics and in vivo therapeutic activity. Synthetic biology has the potential to address these limitations through the generation of highly stable antigenic “mimics” using subunits that do not exist in the natural world. We developed a platform based on D–amino acid combinatorial chemistry and used this platform to reverse engineer a fully artificial CD8+ T cell agonist that mirrored the immunogenicity profile of a native epitope blueprint from influenza virus. This nonnatural peptide was highly stable in human serum and gastric acid, reflecting an intrinsic resistance to physical and enzymatic degradation. In vitro, the synthetic agonist stimulated and expanded an archetypal repertoire of polyfunctional human influenza virus–specific CD8+ T cells. In vivo, specific responses were elicited in naive humanized mice by subcutaneous vaccination, conferring protection from subsequent lethal influenza challenge. Moreover, the synthetic agonist was immunogenic after oral administration. This proof-of-concept study highlights the power of synthetic biology to expand the horizons of vaccine design and therapeutic delivery.
Z Zella Waist Leggings High By Daily r5F14cWgr & trexyourex.com | 2018
John J. Miles; Mai Ping Tan; Garry Dolton; Sarah A.E. Galloway; Bruno Laugel; Mathew Clement; Julia Makinde; Kristin Ladell; Katherine K. Matthews; Thomas S. Watkins; Katie Tungatt; Yide Wong; Han Siean Lee; Richard J. Clark; Johanne M. Pentier; Meriem Attaf; Anya Lissina; Ann Ager; Awen Gallimore; Pierre J. Rizkallah; Stephanie Gras; Jamie Rossjohn; Scott R. Burrows; David K. Cole; David A. Price; Andrew K. Sewell
Polypeptide vaccines effectively activate human T cells but suffer from poor biological stability, which confines both transport logistics and in vivo therapeutic activity. Synthetic biology has the potential to address these limitations through the generation of highly stable antigenic “mimics” using subunits that do not exist in the natural world. We developed a platform based on D–amino acid combinatorial chemistry and used this platform to reverse engineer a fully artificial CD8+ T cell agonist that mirrored the immunogenicity profile of a native epitope blueprint from influenza virus. This nonnatural peptide was highly stable in human serum and gastric acid, reflecting an intrinsic resistance to physical and enzymatic degradation. In vitro, the synthetic agonist stimulated and expanded an archetypal repertoire of polyfunctional human influenza virus–specific CD8+ T cells. In vivo, specific responses were elicited in naive humanized mice by subcutaneous vaccination, conferring protection from subsequent lethal influenza challenge. Moreover, the synthetic agonist was immunogenic after oral administration. This proof-of-concept study highlights the power of synthetic biology to expand the horizons of vaccine design and therapeutic delivery.
Yoga Pant James Riding Perse Perse James xrrwWqXtS & trexyourex.com | 2018
John J. Miles; Mai Ping Tan; Garry Dolton; Sarah A.E. Galloway; Bruno Laugel; Mathew Clement; Julia Makinde; Kristin Ladell; Katherine K. Matthews; Thomas S. Watkins; Katie Tungatt; Yide Wong; Han Siean Lee; Richard J. Clark; Johanne M. Pentier; Meriem Attaf; Anya Lissina; Ann Ager; Awen Gallimore; Pierre J. Rizkallah; Stephanie Gras; Jamie Rossjohn; Scott R. Burrows; David K. Cole; David A. Price; Andrew K. Sewell
Polypeptide vaccines effectively activate human T cells but suffer from poor biological stability, which confines both transport logistics and in vivo therapeutic activity. Synthetic biology has the potential to address these limitations through the generation of highly stable antigenic “mimics” using subunits that do not exist in the natural world. We developed a platform based on D–amino acid combinatorial chemistry and used this platform to reverse engineer a fully artificial CD8+ T cell agonist that mirrored the immunogenicity profile of a native epitope blueprint from influenza virus. This nonnatural peptide was highly stable in human serum and gastric acid, reflecting an intrinsic resistance to physical and enzymatic degradation. In vitro, the synthetic agonist stimulated and expanded an archetypal repertoire of polyfunctional human influenza virus–specific CD8+ T cells. In vivo, specific responses were elicited in naive humanized mice by subcutaneous vaccination, conferring protection from subsequent lethal influenza challenge. Moreover, the synthetic agonist was immunogenic after oral administration. This proof-of-concept study highlights the power of synthetic biology to expand the horizons of vaccine design and therapeutic delivery.
Workshop Terry Dress Hooded French Short Sleeve q8xaAqZ7n & trexyourex.com | 2018
John J. Miles; Mai Ping Tan; Garry Dolton; Sarah A.E. Galloway; Bruno Laugel; Mathew Clement; Julia Makinde; Kristin Ladell; Katherine K. Matthews; Thomas S. Watkins; Katie Tungatt; Yide Wong; Han Siean Lee; Richard J. Clark; Johanne M. Pentier; Meriem Attaf; Anya Lissina; Ann Ager; Awen Gallimore; Pierre J. Rizkallah; Stephanie Gras; Jamie Rossjohn; Scott R. Burrows; David K. Cole; David A. Price; Andrew K. Sewell
Polypeptide vaccines effectively activate human T cells but suffer from poor biological stability, which confines both transport logistics and in vivo therapeutic activity. Synthetic biology has the potential to address these limitations through the generation of highly stable antigenic “mimics” using subunits that do not exist in the natural world. We developed a platform based on D–amino acid combinatorial chemistry and used this platform to reverse engineer a fully artificial CD8+ T cell agonist that mirrored the immunogenicity profile of a native epitope blueprint from influenza virus. This nonnatural peptide was highly stable in human serum and gastric acid, reflecting an intrinsic resistance to physical and enzymatic degradation. In vitro, the synthetic agonist stimulated and expanded an archetypal repertoire of polyfunctional human influenza virus–specific CD8+ T cells. In vivo, specific responses were elicited in naive humanized mice by subcutaneous vaccination, conferring protection from subsequent lethal influenza challenge. Moreover, the synthetic agonist was immunogenic after oral administration. This proof-of-concept study highlights the power of synthetic biology to expand the horizons of vaccine design and therapeutic delivery.
Velvet One Parker Shoulder Rima Blouse qatfAwx7z & trexyourex.com | 2018
John J. Miles; Mai Ping Tan; Garry Dolton; Sarah A.E. Galloway; Bruno Laugel; Mathew Clement; Julia Makinde; Kristin Ladell; Katherine K. Matthews; Thomas S. Watkins; Katie Tungatt; Yide Wong; Han Siean Lee; Richard J. Clark; Johanne M. Pentier; Meriem Attaf; Anya Lissina; Ann Ager; Awen Gallimore; Pierre J. Rizkallah; Stephanie Gras; Jamie Rossjohn; Scott R. Burrows; David K. Cole; David A. Price; Andrew K. Sewell
Polypeptide vaccines effectively activate human T cells but suffer from poor biological stability, which confines both transport logistics and in vivo therapeutic activity. Synthetic biology has the potential to address these limitations through the generation of highly stable antigenic “mimics” using subunits that do not exist in the natural world. We developed a platform based on D–amino acid combinatorial chemistry and used this platform to reverse engineer a fully artificial CD8+ T cell agonist that mirrored the immunogenicity profile of a native epitope blueprint from influenza virus. This nonnatural peptide was highly stable in human serum and gastric acid, reflecting an intrinsic resistance to physical and enzymatic degradation. In vitro, the synthetic agonist stimulated and expanded an archetypal repertoire of polyfunctional human influenza virus–specific CD8+ T cells. In vivo, specific responses were elicited in naive humanized mice by subcutaneous vaccination, conferring protection from subsequent lethal influenza challenge. Moreover, the synthetic agonist was immunogenic after oral administration. This proof-of-concept study highlights the power of synthetic biology to expand the horizons of vaccine design and therapeutic delivery.
Vanity Room Midi Neck Dress Knit Mock Popover H7w8a & trexyourex.com | 2018
John J. Miles; Mai Ping Tan; Garry Dolton; Sarah A.E. Galloway; Bruno Laugel; Mathew Clement; Julia Makinde; Kristin Ladell; Katherine K. Matthews; Thomas S. Watkins; Katie Tungatt; Yide Wong; Han Siean Lee; Richard J. Clark; Johanne M. Pentier; Meriem Attaf; Anya Lissina; Ann Ager; Awen Gallimore; Pierre J. Rizkallah; Stephanie Gras; Jamie Rossjohn; Scott R. Burrows; David K. Cole; David A. Price; Andrew K. Sewell
Polypeptide vaccines effectively activate human T cells but suffer from poor biological stability, which confines both transport logistics and in vivo therapeutic activity. Synthetic biology has the potential to address these limitations through the generation of highly stable antigenic “mimics” using subunits that do not exist in the natural world. We developed a platform based on D–amino acid combinatorial chemistry and used this platform to reverse engineer a fully artificial CD8+ T cell agonist that mirrored the immunogenicity profile of a native epitope blueprint from influenza virus. This nonnatural peptide was highly stable in human serum and gastric acid, reflecting an intrinsic resistance to physical and enzymatic degradation. In vitro, the synthetic agonist stimulated and expanded an archetypal repertoire of polyfunctional human influenza virus–specific CD8+ T cells. In vivo, specific responses were elicited in naive humanized mice by subcutaneous vaccination, conferring protection from subsequent lethal influenza challenge. Moreover, the synthetic agonist was immunogenic after oral administration. This proof-of-concept study highlights the power of synthetic biology to expand the horizons of vaccine design and therapeutic delivery.